Archive for October, 2014

(CAPR) to Hold Third Quarter 2014 Business Update Conference Call

LOS ANGELES, Oct. 31, 2014 — Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Company management will hold a conference call to discuss third quarter 2014 business highlights on Wednesday, November 12, 2014, at 4:30 p.m. ET.

On the call, Dr. Linda Marbán, Chief Executive Officer, will review Capricor’s recent accomplishments, provide an update on the clinical development program of the Company’s lead product candidate, CAP-1002, and discuss other Company updates.

Participants can register for the call and webcast via the following link: Once registered for the call, interested parties will receive the conference call dial-in information. An archived version of the webcast will remain on the Company’s Investors page at

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on August 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

CONTACT: For more information, please contact:

         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance

         ProActive Capital Group
         Kirin Smith, COO
Friday, October 31st, 2014 Uncategorized Comments Off on (CAPR) to Hold Third Quarter 2014 Business Update Conference Call

(ARCW) CEO Featured Panelist at “Make it in America”

DELAND, Fla., Oct. 31, 2014  — ARC Group Worldwide, Inc. (NASDAQ: ARCW), a leading global provider of advanced manufacturing and 3D printing solutions, today announced that its CEO, Jason Young, will be a featured panelist at “Make it in America”, an event focused on the resurgence of U.S. manufacturing. Corridor Capital is hosting the event in Los Angeles on November 4, 2014. Mr. Young will be joining a panel of experts from the Milken Institute, McKinsey, Oaktree Capital and The National Association of Manufacturers to discuss the drivers of the new American manufacturing sector. For more information on the sold-out event, please visit

About ARC Group Worldwide, Inc.

ARC Group Worldwide is a leading global advanced manufacturing and 3D printing service provider.  Founded in 1987, the Company offers its customers a compelling portfolio of advanced manufacturing technologies and cutting-edge capabilities to improve the efficiency of traditional manufacturing processes and accelerate their time to market. In addition to being a world leader in metal injection molding (“MIM”), ARC has significant expertise in 3D printing and imaging, materials science, advanced tooling, automation, machining, stamping, plastic injection molding, lean manufacturing, and robotics. For more information about ARC Group Worldwide, please visit, or its operating subsidiaries at,,,,,,,,,,, and


This press release may contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are based on ARC’s current expectations, estimates and projections about future events. These include, but are not limited to, statements, if any, regarding business plans, pro-forma statements and financial projections, ARC’s ability to expand its services and realize growth. These statements are not historical facts or guarantees of future performance, events or results. Such statements involve potential risks and uncertainties, and the general effects of financial, economic, and regulatory conditions affecting our industries. Accordingly, actual results may differ materially. ARC does not have any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For additional factors that may affect future results, please see filings made by ARC with the Securities and Exchange Commission (“SEC”), including its Form 10-K for the fiscal year ended June 30, 2013 and Form 10-Q for the period ended March 30, 2014, as well as current reports on Form 8-K filed from time-to-time with the SEC.

CONTACT: Drew M. Kelley

PHONE: (303) 467-5236


Friday, October 31st, 2014 Uncategorized Comments Off on (ARCW) CEO Featured Panelist at “Make it in America”

(GCAP) to Acquire City Index and Announces Record Preliminary Third Quarter Results

– Transaction creates global leader in FX/CFD trading, with over 235,000 funded accounts, $1.2 billion in customer assets and $3.1 trillion in annual trading volume – – Transaction adds significant scale to GAIN’s retail business – – Results in estimated operating synergies of $45 million-$55 million within two years – – Preliminary third quarter 2014 results include record revenues of $103 million, up 69% – – Adjusted EBITDA* of $26.6 million, up 120%; 26% adjusted EBITDA Margin* – – Net income of $14.7 million, or $0.32 per share, up from $5.6 million or $0.14 per share – (*See below for reconciliation of non-GAAP financial measures)

BEDMINSTER, N.J., Oct. 31, 2014  — GAIN Capital Holdings, Inc. (NYSE: GCAP, “GAIN”), today announced that it has entered into a definitive agreement to acquire City Index (Holdings) Limited (“City Index”), a leading online trading firm specializing in contracts-for-difference (CFDs), forex and UK spread betting, for approximately $118 million1, or a net purchase price of $82 million, including $36 million in cash on the company’s balance sheet.

The combination of GAIN Capital and City Index creates a global leader in online trading, operating two market-leading brands in GAIN’s, a top retail forex brand globally, and City Index, a premier CFD and spread bet brand. The combined company will service 235,000 retail customers in over 180 countries with annual trading volumes of more than $3 trillion.

“The acquisition of City Index advances our growth strategy, creating scale for our retail business and accelerates the development of our innovative trading technology,” said Glenn Stevens, GAIN’s chief executive officer. “The combination will result in a balanced mix of customer volume, with approximately 61% of retail volume coming from FX and 39% from CFD trading/UK spread betting in other asset classes such as equities, indices and commodities. We look forward to leveraging the City Index brand in key markets and working with the team at City Index, who share our commitment to creating a superior customer experience.”

“This transaction is a landmark moment in City Index’s 30-year history as a leader in retail trading,” said Mark Preston, City Index’s Chairman and Chief Executive. “The combination of GAIN’s unrivalled leadership in global foreign exchange with City Index’s internationally-recognized CFD business creates a world-class industry leader, providing the scale and capability to deliver the ultimate trading experience to our clients around the world. The combined business will also offer greater opportunities for City Index’s management and staff to flourish in a global business.”

Founded in London in 1983 as one of UK’s first spread betting companies, City Index is today one of the world’s leading providers of CFDs, forex and UK spread betting, offering more than 10,000 products across equity, index, FX, commodity and bond CFDs and spread bets. City Index is majority owned by IPGL, the private holding company for the interests of Michael Spencer, Founder and Chief Executive of ICAP plc, the global markets operator.

“I am very pleased we have been able to agree to this transaction, which brings benefits for everyone,” said Michael Spencer. “I believe GAIN is an outstanding company and will be able to move City Index to the next level, by leveraging its broad array of trading products and services onto a global platform. We believe this combination will enhance GAIN’s leadership position in the FX/CFD industry by putting together two highly complementary companies to create significant value for customers and stakeholders. This is the latest example of the way that IPGL is able to invest actively in businesses over the long term to support their growth and development.”

For the 12 month period ended September 30, 2014, City Index generated $124.8 million in revenue and $10.7 million in adjusted EBITDA. It had approximately 104,000 funded retail accounts and $344 million in customer assets as of September 30, 2014.

The combined company will have pro forma client assets of approximately $1.2 billion, and trailing twelve month revenues and adjusted EBITDA, for the period ended September 30, 2014, of $462 million and $61 million, respectively. GAIN has identified $45 million – $55 million of fixed operating expense synergies, relative to the combined company’s trailing twelve-month expenses, and expects to begin realizing theses synergies promptly after closing with full integration achieved over the ensuing 18-24 months. GAIN expects for this acquisition to become highly accretive over this time period and anticipates achieving accretive results by the fourth quarter following closing.

The transaction follows the successful acquisition and integration of GFT, which closed in September 2013, where GAIN Capital achieved approximately $40 million of run rate expense synergies.

City Index clients will not see any immediate impact to the customer service they receive, their account administration or how they trade. All clients will receive more detailed information about the benefits the combined company can offer them, once the acquisition is completed.

Terms of the Transaction

The purchase price will consist of $20 million in cash, $60 million of convertible notes and the issuance of approximately 5.3 million GAIN shares. The total purchase price of $118 million represents a $28 million premium above City Index’s book value as of September 30, 2014.

In addition to the $36 million of cash on its books as of September 30, 2014, City Index also has $65 million of net operating losses which can be carried forward following the closing of the transaction.

The transaction is subject to approval by GAIN Capital stockholders, regulatory approvals and customary closing conditions. The deal is expected to close in the first quarter of 2015.

Jefferies LLC is serving as exclusive financial advisor to GAIN Capital. Keefe, Bruyette & Woods, A Stifel Company is serving as financial advisor to IPGL. Davis Polk & Wardwell advised GAIN Capital on U.S. and UK legal matters.  Macfarlanes advised IPGL and City Index on UK legal matters and Kirkland & Ellis advised IPGL and City Index on U.S. legal matters.

City Index Acquisition Conference Call

GAIN will host a conference call today, Friday, October 31, 2014 at 8.00 a.m. ET.  Participants may access the live call by dialing + 1-866-652-5200 (U.S. domestic), or + 1-412-317-6060 (international).

A live audio webcast of the call and a copy of the accompanying presentation will also be available on the Investor Relations section of the GAIN website ( A PDF copy of the presentation will also be available on the Investor Relations website.

An audio replay will be made available for one month starting approximately two hours after the call by dialing + 1-877-344-7529 in the U.S. or + 1-412-317-0088 from abroad, and entering passcode 10055502#

Preliminary Third Quarter Results

GAIN Capital also announced today preliminary results for the third quarter ended September 30, 2014. Net revenues for the third quarter ended September 30, 2014 were a record $102.8 million, an increase of 69% from $60.8 million from a year earlier. Adjusted EBITDA for the period was $26.6 million, an increase of 120% from $12.1 million from a year earlier. Net income was $14.7 million, or $0.32 per diluted share, up 163% from $5.6 million, or $0.14 per diluted share a year earlier. Cash earnings per share, which reflect earnings per share less the impact of depreciation and amortization, purchased intangible amortization and non-cash interest was $0.40 per diluted share, an increase of 124% from a year earlier. The Company will review its full third quarter results on Thursday November 6, 2014 during a conference call scheduled for 8:00 a.m. Details for the conference call with be forthcoming.

About GAIN Capital

GAIN Capital Holdings, Inc. (NYSE: GCAP) provides innovative trading technology and execution services to retail and institutional investors worldwide, with multiple access points to OTC markets and global exchanges across a wide range of asset classes, including foreign exchange, commodities, and global equities. GAIN Capital is headquartered in Bedminster, New Jersey, with a global presence across North America, Europe and the Asia Pacific regions. For further company information, visit

About City Index

City Index (Holdings) Ltd. is a global provider of retail trading services including spread betting (UK only), CFDs and margin forex. Established in 1983, the firm trades primarily under the City Index, Finspreads, FX Solutions and IFX Markets brands with core markets in the UK, Middle East and the Asia Pacific.
For further company information, visit

(*) Reconciliation of Net Income to Cash Net Income and Cash EPS

Cash net income is a non-GAAP financial measure and represents our net income excluding depreciation and amortization, purchased intangible amortization and non-cash interest expense. This non-GAAP financial measure has certain limitations, including that it does not have a standardized meaning and, therefore, our definition may be different from similar non-GAAP financial measures used by other companies and/or analysts. Thus, it may be more difficult to compare our financial performance to that of other companies. We believe our reporting of cash net income assists investors in evaluating our operating performance. However, because cash net income is not a measure of financial performance calculated in accordance with GAAP, such measure should be considered in addition to, but not as a substitute for, other measures of our financial performance reported in accordance with GAAP, such as net income.


Reconciliation of GAAP Net Income to Cash Net Income and Cash EPS
In thousands, except per share data
Three Months Ended
September 30,
2014 2013
Net income $ 14.7 $ 5.6
Add Back; net of tax:
Depreciation & Amortization 1.5 1.2
Purchased Intangible Amortization 1.5 0.3
Non-cash Interest Expense 0.4
Cash net income 18.1 7.1
Basic $ 0.42 $ 0.20
Diluted $ 0.40 $ 0.18
Weighted averages common shares outstanding
in computing earnings per common share:
Basic 41,038,782 36,062,659
Diluted 43,523,862 39,730,857

Reconciliation of GAAP Net Income to Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is a non-GAAP financial measure that represents our earnings before interest, taxes, depreciation and amortization, restructuring, acquisition and integration-related expenses, impairment on investment and gain on extinguishment of debt. This non-GAAP financial measure has certain limitations, including that it does not have a standardized meaning and, therefore, our definition may be different from similar non-GAAP financial measures used by other companies and/or analysts. Thus, it may be more difficult to compare our financial performance to that of other companies. We believe our reporting of adjusted EBITDA assists investors in evaluating our operating performance. However, because adjusted EBITDA is not a measure of financial performance calculated in accordance with GAAP, such measure should be considered in addition to, but not as a substitute for, other measures of our financial performance reported in accordance with GAAP, such as net income.

Adjusted EBITDA Margin is adjusted EBITDA over net revenue.


Reconciliation of GAAP Net Income to Adjusted EBITDA and Adjusted EBITDA Margin (GAIN)
In millions
Three Months Ended Trailing 12 Months
September 30, September 30
2014 2013 2014
Net revenue $ 102.8 $ 60.8 $ 337.3
Net income 14.7 5.6 17.7
Net income margin % 14 % 9 % 5 %
Net income $ 14.7 $ 5.6 $ 17.7
Depreciation and amortization 2.0 1.9 8.6
Purchased intangible amortization 2.0 0.5 5.8
Interest expense 1.5 0.2 5.5
Income tax expense 5.1 3.0 7.0
Acquisition & integration costs 0.9 0.5 3.9
Restructuring 0.4 0.4 2.2
Adjusted EBITDA 26.6 12.1 50.7
Adjusted EBITDA Margin 26 % 20 % 15 %


Reconciliation of GAAP Net Income to Adjusted EBITDA and Adjusted EBITDA Margin (City Index)
In millions
Trailing 12 Months
September 30
Net revenue $   124.8
Net income $   (17.0)
Depreciation & amortization 24.4
One-time expenses 3.3
Adjusted EBITDA 10.7


Pro Forma Amounts

All pro forma amounts represent the combination of GAIN and City Index via simple addition.

Forward Looking Statements

The forward-looking statements contained herein include, without limitation, statements relating to GAIN Capital’s and/or City Index (Holdings) Limited (“City Index”) expectations regarding the opportunities and strengths of the combined company created by the proposed business combination, anticipated cost and revenue synergies, the strategic rationale for the proposed business combination, including expectations regarding product offerings, growth opportunities, value creation, and financial strength, and the timing of the closing.  All forward looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that GAIN Capital or City Index will realize these expectations or that these beliefs will prove correct. In addition, a variety of important factors could cause results to differ materially from such statements. These factors are noted throughout GAIN Capital’s annual report on Form 10-K, as filed with the Securities and Exchange Commission on March 17, 2014, and include, but are not limited to, the actions of both current and potential new competitors, fluctuations in market trading volumes, financial market volatility, evolving industry regulations, including changes in regulation of the futures companies, errors or malfunctions in GAIN Capital’s systems or technology, rapid changes in technology, effects of inflation, customer trading patterns, the success of our products and service offerings, our ability to continue to innovate and meet the demands of our customers for new or enhanced products, our ability to successfully integrate assets and companies we have acquired, our ability to effectively compete in the futures industry, changes in tax policy or accounting rules, fluctuations in foreign exchange rates and commodity prices, adverse changes or volatility in interest rates, as well as general economic, business, credit and financial market conditions, internationally or nationally, and our ability to continue paying a quarterly dividend in light of future financial performance and financing needs. The forward-looking statements included herein represent GAIN Capital’s views as of the date of this release. GAIN Capital undertakes no obligation to revise or update publicly any forward-looking statement for any reason unless required by law.

1 The estimated total transaction value is based on the closing price of GAIN Capital common stock on October 30, 2014. The purchase price for accounting purposes will be determined upon the closing of the acquisition and will depend on GAIN Capital’s stock price at that time.

Friday, October 31st, 2014 Uncategorized Comments Off on (GCAP) to Acquire City Index and Announces Record Preliminary Third Quarter Results

(ZYXI) Schedules Third Quarter 2014 Earnings Release and Webcast

LONE TREE, CO–(Oct 31, 2014) – Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today that it will host the Company’s third quarter investor webcast on Friday, November 7 at 9:00 a.m. Mountain Time – 11:00 a.m. Eastern Time.

The Company expects to release third quarter results on Friday, November 7, 2014 prior to the market open.

Webcast Details: Friday, November 7, 2014 at 9:00 a.m. MT – 11:00 a.m. ET

To register and participate in the webcast, interested parties should click on the following link approximately 10-15 minutes prior to the webcast:

Please note: questions can only be submitted via the webcast user interface. Parties without access to the internet may join the presentation in listen only mode by dialing the toll free number provided below.

Phone Access Details:
Participant Toll Free Dial-in Number: 888-364-3109
Participant Phone Access Passcode: 8055032

About Zynex
Zynex, founded in 1996, operates under five primary business segments: Zynex Medical, NeuroDiagnostics, Monitoring Solutions, International, and Billing and Consulting. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex Medical’s product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex Medical also operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex NeuroDiagnostics sells and distributes EMG, EEG, sleep pattern, auditory and nerve conductivity neurological devices. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring. Zynex International is dedicated to supporting sales and marketing of Zynex products worldwide through a network of medical distributors. Zynex Billing and Consulting division provides medical billing and consulting service for offices and hospitals.

For additional investor information, please visit:

Safe Harbor Statement

Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumstances, information currently available, and assumptions about future revenues, industry growth, and general economic conditions. Estimates are inherently uncertain as they are based on assumptions concerning future events. No representations can be made as to the accuracy of such information or the reliability of such assumptions. Accordingly, actual revenues and expenditures may vary significantly from the Company’s estimates, and actual results or developments may differ materially from those expressed or implied by the forward-looking statements. Factors that could cause actual results to differ from the financial estimates and forward-looking statements in this presentation include those described in the Company’ s filings with the Securities and Exchange Commission, including the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Therefore, neither the Company’s estimates nor the assumptions upon which they are based are to be interpreted as a guarantee or promise of the Company or management. The Company has no obligation to modify, amend, update, alter, or change the estimates contained herein.

Zynex, Inc.

Friday, October 31st, 2014 Uncategorized Comments Off on (ZYXI) Schedules Third Quarter 2014 Earnings Release and Webcast

(VTMB) Continues Double Digit Growth

COSTA MESA, CA–(Oct 31, 2014) – Vitamin Blue (PINKSHEETS: VTMB) Vitamin Blue, Inc. is pleased to announce revenues for the third quarter of 2014 continued its double digit growth with an 83% increase in sales year over year. Sales were primarily through the Vitamin Blue line of custom board bags and other products purchased through Amazon, eBay and the company website.

“Our double digit growth is an indication that our brand and products are gaining a foot hold in this industry,” commented Frank Ornelas, CEO of Vitamin Blue. “We are starting to see increased referrals, repeat customers and OEM opportunities. All an indication of strong brand recognition and speaks volumes to the impact we are making on our customers with our philosophy of quality products and strong customer service.”

About Vitamin Blue, Inc. (

Vitamin Blue designs, develops, produces and distributes water boardsports apparel, accessories and related products. Founded in 1999, the Costa Mesa, California based company in part of the consumer goods sector and non-durables industry.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plans and strategies. Although we believe that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements, including, without limitation, the factors described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Securities and Exchange Commission filings.

Friday, October 31st, 2014 Uncategorized Comments Off on (VTMB) Continues Double Digit Growth

(NSAV) Announces the Execution of a Due Diligence Evaluation

PORT JEFFERSON, NY, United States, via ETELIGIS INC., 10/31/2014 – – Net Savings Link, Inc. (OTC Pink: NSAV) (PINKSHEETS: NSAV) today has announced the execution of an agreement by our new President, Leonard F. Genovese, on behalf of NSAV, to conduct a formal due diligence evaluation for purposes of a targeted merger/acquisition with a well-established firm that has an entrenched and long term presence in the Artisanal food and beverage/wellness/ and retail distribution space in the Northeastern portion of the U.S., and is expanding nationally. Mr. Genovese commented; This is an exciting opportunity to pair the synergy of this firm with NSAV. The targeted firm has existing revenues with year over year growth for the past 3 fiscal terms, and has an established customer base that encompasses both a retail and institutional model. Mr. Genovese continued; The firm not only has a domestic presence, but also has a European base that brings significant product variety into existing domestic markets that we are optimistic to enter. They are a leader in imported foods from certain European markets, and they hold various proprietary food packaging agreements that will enhance product diversity. Mr. Genovese continued; we are optimistic that we will close on this agreement, pending the outcome of our D.D. evaluation, within the next 30-60 days.

Steven Baritz, the CEO of NSAV said, NSAV s recent decision to appoint Mr. Genovese has proven to already pay dividends in terms of corporate development, intermediate growth, and strategy. Mr. Genoveses mature contact base has expressed an eagerness to be a part of a firm that he is operating within a leadership capacity. Baritz continued, We are expressing extreme optimism that this will be the first of many strategic growth opportunities that Mr. Genovese will facilitate for NSAV, and we are certain that they will be well received by both the consumer as well as the shareholder and investor community. We will provide a subsequent update on the status of this announcement in a subsequent release upon the conclusion of the due diligence evaluation.

Mr. Baritz also commented on a recent concern of shareholders regarding the removal of the DTC chill; NSAV has made one of its top priorities, the removal of the DTC chill that has existed prior to the current management teams tenure on the Board. Baritz continued; It is apparent that in order for NSAV to move to the next level that will be commensurate with our intermediate and long term objectives, the removal of the chill will be of paramount importance, and we expect to commence the process to remove the chill as soon as certain self- imposed metrics are achieved in regard to capital availability and revenue expectations.

About Net Savings Link, Inc.:

Net Savings Link, Inc. owns and operates a wholly owned subsidiary, Global Distribution Corporation, a distribution company that markets and distributes products in varying industries including the supplement, wellness and natural remedies markets. People interested in learning more about Global Distribution should check back with the company at its website,

DISCLAIMER: This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information contained in this Press Release including such forward-looking statements.


David Pecoraro

Shareholder Relations Director


Tel: 814-418-6648

Friday, October 31st, 2014 Uncategorized Comments Off on (NSAV) Announces the Execution of a Due Diligence Evaluation

(YEWB) Applauds China State Forestry Admin’s Subsidy Of Medicinal Herb Crops

HARBIN, China, Oct. 30, 2014  — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber, today applauded the creation of a subsidy program by the State Forestry Administration of China to promote the development and growth of Chinese medicinal herb crops.

The central China government continues to increase financial support to the national forest economy in efforts to promote the proportion of investment in other sectors of planting, and to help forestry and growers become a new economic growth point. Heilongjiang Provincial Forestry Department, where Yew Bio-Pharm is located, was recently selected to receive initial subsidies for undergrowth planting of Chinese medicine herbs.

Under Heilongjiang Province’s Forest Economic Development Plan, which was announced in January 2014, the forest economy in the province is expected to reach 150 billion yuan (approximately US$24.5 billion) by 2020. The plan focuses on developing Chinese medicine, forest mushrooms, berries, vegetables, seeds and other undergrowth corps.

“As a leading yew tree grower in the region, and producer of traditional Chinese medicine used in certain cancer treatments, we are very encouraged by this positive development,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “The subsidies should help spur development of new projects and incentivize economic growth in the region for growers of traditional Chinese medicine crops.”

“With our advanced planting technologies, and one of the largest yew forests in China with more than 20,000 MU (approximately 3,300 acres), we are optimistic about the possibility of receiving the national financial support. Through this funding, we can further utilize the company’s 1 million MU (approximately 165,000 acres) of forestland to plant globally scarce anti-cancer medicine herbs,” Wang added.


Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit

Company Contacts:Henry Pang

Yew Bio-Pharm Group, Inc.

Tel: (702) 487-4683

Investor Relations Contacts:Judy Lin Sfetcu

PondelWilkinson Inc.

Tel: 310-279-5980

Thursday, October 30th, 2014 Uncategorized Comments Off on (YEWB) Applauds China State Forestry Admin’s Subsidy Of Medicinal Herb Crops

(SWRF) Provides an Update on the Completion of SoOum Merger

New York, NY / October 30, 2014 / Swordfish Financial, Inc. (OTC:SWRF) provides a shareholder update regarding the process of the pending Swordfish/SoOum merger.

SWRF is pleased to report the final steps of the forthcoming merger with SoOum Corp. SWRF has contracted a leading provider in investor communications and financial printing, to distribute the information statement (Schedule 14f-1) as officially required as part of completing the merger. The printing has been completed and the mailing in process. The certification that this information statement is being delivered to shareholders of record, along with a FINRA filing, and final forms to the US SEC, enables closing. SWRF has been advised that final merger can occur in approximately fourteen (14) days.

SoOum CEO, William Westbrook, reported that, “The motivation, morale and vision of the entire upper management in SoOum is healthy and increasing. The merger with Swordfish, which is nearing its completion, fulfills SoOum’s demand for new talent, specialized experience, technology and market reaches.”

Luis Vega, SoOum’s, Chief Operation and Trade Officer, reports they have seen a significant increase in new trade opportunities due to the publicity it has received from its merger announcement,

Also of note, in development news, SoOum has been working with Trade Risk Group ( in attaining credit insurance for its top importers, thereby enabling the Company to offer a broader range of payment terms to its leading customers and enhancing its capacity to grow with less risk.

For further information regarding this release, contact Rich Kaiser, Business Consultant, YES INTERNATIONAL, 757-306-6090 and/or

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to matters such as prospects, anticipated operating and financial performance. Actual prospects and performance may differ from anticipated results due to economic conditions and other risks, uncertainties and circumstances partly or totally outside the control of the Company, including risks of market volatility, the level of capital expenditures required to fund ongoing trading operations and the ability of the Company to execute its business strategy. These and other risks are described in the Company’s reports filed with the United States Securities and Exchange Commission. These forward-looking statements are made only as of the date of this communication and the Company undertakes no obligation to update or revise these forward-looking statements.

Rich Kaiser

Thursday, October 30th, 2014 Uncategorized Comments Off on (SWRF) Provides an Update on the Completion of SoOum Merger

(OMER) Omidria™ Granted Pass-Through Reimbursement Status from CMS

— Unique Billing Code Allows Separate Payment for Omidria —

SEATTLE, Oct. 30, 2014  — Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Approved earlier this year by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement (ILR), Omidria is the only FDA-approved product for intraocular administration that prevents intraoperative miosis (pupil constriction) and reduces postoperative pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other ILR procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015.

Transitional pass-through status will allow ambulatory surgery centers and other outpatient facilities to bill Medicare and other insurance providers for Omidria using a temporary Healthcare Common Procedure Coding System (HCPCS) code unique to Omidria. Pass‑through status allows for separate payment for new drugs and other medical technologies that meet specific clinical-value and cost requirements. Pass‑through remains in effect for a period of two to three years, after which time CMS and other insurance providers make a new reimbursement determination. Pass‑through status for Omidria will become effective on January 1, 2015, and reimbursement will be based on the product’s wholesale acquisition cost of between $400 and $500 per single-use vial.

“We are pleased with CMS’s decision to grant pass-through for Omidria,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Pass-through status should streamline the billing and reimbursement process for facilities that use Omidria and could accelerate adoption of the product across cataract and other intraocular lens procedures. Coincident with this new clarity on reimbursement, our commercial team is in the process of adding the second wave of sales representatives, and we plan to launch Omidria no later than early 2015.”

About Omidria
Omeros’ PharmacoSurgery® product Omidria (pronounced oh-MID-ree-uh) is a proprietary combination of the mydriatic (pupil-dilating) agent phenylephrine and the anti-inflammatory agent ketorolac, which was developed for use during cataract or other intraocular lens replacement (ILR) surgery. The FDA has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or ILR to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The European Medicines Agency (EMA) is currently reviewing the Marketing Authorization Application (MAA) for Omidria.

Important Risk Information for Omidria

Systemic exposure of phenylephrine may cause elevations in blood pressure. In clinical trials, the most common reported ocular adverse reactions at two to 24 percent are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Omidria must be diluted prior to use. Omidria is not approved for use in children.

About Omeros Corporation

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company’s first drug product, Omidria(phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omeros is completing preparations for a planned U.S. product launch no later than early 2015. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros also has six clinical-stage development programs focused on complement-related thrombotic microangiopathies, Huntington’s disease, schizophrenia, and cognitive impairment; on addictive and compulsive disorders; and on preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with effectiveness of Omidria sales and marketing efforts, Omidria market acceptance, product pricing and reimbursement, Omeros’ ability to obtain regulatory approval for its Marketing Authorization Application in the EU for the commercialization of Omidria, Omeros’ unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Thursday, October 30th, 2014 Uncategorized Comments Off on (OMER) Omidria™ Granted Pass-Through Reimbursement Status from CMS

(SUIP) Licensing Agreement for BreastCare DTS™ With LMT

BreastCare DTS(TM) Is Patented, Non-Invasive, FDA-Cleared Cancer Detection Device; Agreement Gives Sunrise Exclusive Distribution Rights in US, Canada, China

NEW YORK, NY–(Oct 30, 2014) –  Sunrise Holdings, Limited, a Nevada company in the medical device business (OTCQB: SUIP), has entered into a licensing agreement, via its subsidiary Efil Sub of ECG Inc., with Life Medical Technologies, Inc. with respect to Life Medical’s “BreastCare DTS™ device” and certain other derivative technologies. The License Agreement grants Efil the exclusive right to distribute the BreastCare DTS™ in the United States, Canada and certain countries in Asia, including China. The Agreement calls for payment by Efil to Life Medical of royalties of 5% on net sales by Efil and requires payment by Efil of minimum annual royalties of $100,000 in 2015 and $200,000 each year thereafter. The Agreement also calls for payment by Life Medical to Efil of royalites of 5% on net sales by Life Medical.

The BreastCare DTS™ is a patented, non-invasive and FDA-cleared as an adjunct to mammography and other established procedures for the detection of breast disease, including breast cancer. DTS stands for “Differential Temperature Sensor,” indicating the ability of the device to compare temperatures in one area of the breast with others in the same breast and the other breast.

John Bentivoglio, President and CEO of Sunrise Holdings, said, “This agreement brings a marvelous technology into our growing stable of medical devices, and it takes us into the very important field of breast cancer detection. Early detection is crucial to positive outcomes, and detection methods, while effective, can be improved. The BreastCare DTS™ device represents such an improvement, and we believe that the potential market for it is immense.”

Bentivoglio added, “The incidence of breast cancer is highest in the developed world, but by 2020, some estimates have as many as 70 percent of all cases will be found in the developing economies of the world. The BreastCare DTS™ device is well-suited to addressing this trend. As these countries increase their incomes, as they develop, they will be able to spend more on medical care than they do now. This means that demand for effective cancer treatments rather than palliative care will rise, but at the same time, the resources will remain limited. A relatively low-cost device that can capture early stage potential breast cancer data which we believe is exactly what the market will need.

“The global Point of Care market in 2011, is in the order of $18.7 billion, up from $10.3 billion in 2005. In the U.S. alone, the combined breast cancer detection/diagnostic market was valued at more than $2.2 billion in 2008, and is expected to continue in a stable growth pattern over the next several years, Analysts have suggested a conservative growth rate of approximately 5.4% year on year.”

BreastCare DTS™ has received FDA 510K clearance for marketing in the United States and can used by physicians as an adjunct to routine physical examination including palpation, mammography and other established procedures for the detection of breast disease including breast cancer. Clinical studies have been conducted on over 5,000 women in prestigious cancer centers in the U.S., Europe and Latin America, including Memorial Sloan-Kettering in New York and M.D. Anderson in Houston.

The BreastCare DTS™ device consists of two mirror image, lightweight and disposable foam pads with three wafer-thin foil sensors on each pad. Each of the three segments on each pad contains 18 rows of heat-sensitive chemical dots. The device is easy to use and requires no electricity or probes.

The test is completely non-invasive. The pads are easily placed on a woman’s breasts inside the bra for 15 minutes. The device measures the deep heat energy that is transferred to the surface of the skin. Each heat-sensitive dot is calibrated to record the temperature of the surface of the breast. The dots themselves change color from blue to pink when exposed to specific temperatures. The results are clearly displayed and can be immediately evaluated. The heat-sensitive dots have embedded memory, which allows the results to be read after each test is completed.

Bentivoglio concluded, “We believe that BreastCare DTS™ is an exceptional, low-cost Point of Care device that has the potential to save thousands upon thousands of lives. We are focused on bringing it to market by the beginning of 2015, and to that end, we are in final stage negotiations with two engineering firms to begin production in time to meet that deadline. Combined with the Now Cardio™ advanced cardiac monitor being developed by Event Cardio Group Inc, a company we intend to acquire shortly, BreastCare DTS™ represents a significant step forward for our shareholders as well as for patients.”

About Sunrise Holdings
Sunrise Holdings is a Nevada company engaged in the medical device market. It has entered into a Share Exchange Agreement to acquire Event Cardio Group Inc, which is developing a new product, Now Cardio™, an advanced cardiac monitor which offers dual-functionality including both holter monitoring and event recording simultaneously. As a wireless and leadless system, it is more comfortable to wear, and as a result, is more likely to be worn. Based on experience, Event Cardio Group Inc believes it can reach diagnostic yields greater than 90%. Event Cardio Group Inc believes that this would be a meaningful first within the industry.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Information included in this press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Sunrise Holdings Limited (“Sunrise”, “We”, “Our” or the “Company”) to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of words “may,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Our actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

John Bentivoglio
Sunrise Holdings Inc
President and CEO
Email Contact


Michael Porter
Porter, LeVay and Rose
Email Contact

Thursday, October 30th, 2014 Uncategorized Comments Off on (SUIP) Licensing Agreement for BreastCare DTS™ With LMT

(CAPA) acquires the assets of Movie Star News, LLC

LOS ANGELES, Oct. 30, 2014 — Capital Art, Inc., a publicly traded company (CAPA), has announced that it has acquired the assets of Movie Star News, LLC. The Movie Star News archive is believed to be one of the largest and most comprehensive collections of original Hollywood photography and contains more than 100,000 negatives and over 1 million original studio photos, including photos of Marilyn Monroe, Audrey Hepburn, Cary Grant and other iconic Hollywood legends. In addition, the assets consist of the Irving Klaw archive of over 9,000 original camera negatives featuring Bettie Page. Bettie Page is considered by many to be the first pin-up model in history.

Movie Star News began in 1938 when photographer Irving Klaw struck a deal with the movie studios, then operating in New York City, to collect movie photography that was in great demand by Hollywood fans.  Klaw eventually began to create an archive of Hollywood studio original negatives from which prints were made for the media and adoring fans. The collection was moved to Las Vegas, Nevada in August 2012, and when the iconic store on West 18th Street closed, it was hailed as the closing of a New York institution by many national publications.

Irving Klaw is credited for creating the world of pin-up photography. He extensively photographed Bettie Page, who came to be known as the “Queen of Pin-Ups.” The Bettie Page Collection includes over 5,000 negatives, photographs, clothing and other invaluable props.

Capital Art, Inc. sells limited edition, fine art Hollywood prints featuring the Frank Worth Archive, the Movie Star News Archive and the Bettie Page Collection. The company also makes photographs available for publication rights through its agreement with Getty Images.

Thursday, October 30th, 2014 Uncategorized Comments Off on (CAPA) acquires the assets of Movie Star News, LLC

(CDTI) Unveils Breakthrough Clean Air Technology

Initial patents awarded for vehicle exhaust-cleaning technology – Eliminates need for expensive platinum group and rare earth metals

OXNARD, Calif., Oct. 30, 2014  — Clean Diesel Technologies, Inc. (Nasdaq:CDTI) (“CDTi” or “the Company”), a leader in advanced emission control technology, announced the United States Patent and Trademark Office (USPTO) awarded it two new patents covering CDTi’s new technology that replaces costly platinum group and rare earth metals in catalytic converters. These patents represent the first of a family of patents for CDTi’s Spinel™ technology, a proprietary clean emissions exhaust technology that promises to dramatically reduce the cost of attaining more stringent clean air standards.

The new technology will power multiple catalytic product lines that the Company believes have the potential to be highly disruptive to the traditional platinum-based or rare earth-based device industry. This is the Company’s first public announcement regarding its Spinel technology, the development of which has been kept confidential until now.

CEO Chris Harris commented, “Currently global OEMs spend billions of dollars annually on platinum group metals (PGMs) mined in South Africa and Russia, and hundreds of millions of dollars on Chinese-sourced rare earth metals. These costs are expected to dramatically increase with conventional technology as new regulations like U.S. EPA Tier 3 kick in. Spinel technology solves a major industry supply and cost problem and marks a major breakthrough both for us and for all OEMs around the world manufacturing fossil fuel-powered engines.”

About Spinel Technology

  • A family of proprietary materials using various base metals that replace costly PGMs and rare earth metals in coatings on standard catalytic converters
  • Works across a wide range of engine and vehicle applications – both gasoline and diesel
  • Advanced testing underway on production models of popular passenger cars and heavy duty vehicles at respected independent vehicle test facilities

Spinel Technology Significance and Benefits

  • Potential for significant cost savings for OEMs by cutting out expensive PGMs and rare earth metals
  • Currently OEMs spend over $6 billion a year on PGMs (source: derived from Johnson Matthey PLC: Platinum 2013 Interim Review)
  • Enables early, cost-effective compliance with stricter emissions standards in the U.S. and around the world
  • Mitigates OEM exposure to supply uncertainty and price volatility in the PGM and rare earth markets

CTO Dr. Stephen Golden added, “The Spinel technology is the result of hard work and ingenuity by our world-class R&D team. It is an entirely new materials science pathway to meeting tighter regulations at much lower cost. Key validation vehicle testing is underway in parallel with aggressively building a broad IP portfolio as we incorporate Spinel technology into specific products for global OEMs.”

For more information on CDTi’s Spinel technology, please visit

About CDTi

CDTi is a vertically integrated global manufacturer and distributor of emission control systems and products, focused on the light duty vehicle and heavy duty diesel markets. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology and other related technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. CDTi is headquartered in Oxnard, California and currently has operations in the U.S., the U.K., Canada, France, Japan and Sweden. For more information, please visit

About Platinum Groups Metals (PGMs)

Expensive PGM metals, which include platinum, palladium and rhodium, are used in the manufacture of emission control catalysts, with palladium and rhodium being the primary components used in catalysts serving the global light duty vehicle market. According to Johnson Matthey PLC’s “Platinum 2013 Interim Review,” in 2013, over 70% of all primary platinum and 80% of all primary rhodium produced originated in Southern Africa. Russia and Southern Africa combined supplied over 75% of palladium.

About Rare Earth Metals

Rare earth metals such as cerium, neodymium and lanthanum, also referred to as rare earth elements, are chemical elements used in many devices that people use every day, including computers, cell phones, rechargeable batteries and catalytic converters. As the global demand for these devices increases the use of rare earth metals is expected to rise. According to a 2014 U.S. Geological Survey Mineral Commodity Summary, the estimated value of refined rare earth metals imported by the U.S. in 2013 was $260 million. An estimated 79% of rare earth metals used in the U.S. were imported from China with 65% utilized in catalysts.

Forward-Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements. You can identify these forward-looking statements by the use of the words “believes”, “expects”, “anticipates”, “plans”, “may”, “will”, “would”, “intends”, “estimates”, and other similar expressions, whether in the negative or affirmative. Forward-looking statements are based on a series of expectations, assumptions, estimates and projections which involve substantial uncertainty and risk. In this document, the Company includes forward looking statements regarding the anticipated or potential benefits of Spinel™ technology, anticipated increases in OEM expenditures on PGMs and rare earth metals with conventional technology, the effects of new regulations, additions to CDTi’s IP portfolio in parallel with continued vehicle testing, the incorporation of Spinel™ technology into products for OEMs, and the effects of Spinel™ technology on the traditional platinum-based or rare-earth based device industry and demand for platinum group and rare earth metals. In general, actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including, but not limited, to (a) any inability by CDTi to (i) reduce costs; (ii) increase sales; (iii) realize benefits of investments; (iv) obtain sufficient funding; (v) realign its strategic path; (vi) execute its strategic priorities; (vii) commercialize its technology due to agreements with third parties; (viii) protect its intellectual property; (ix) obtain verifications, approvals or market acceptance of its products or technology; (x) attract or retain qualified personnel; (xi) achieve anticipated results; (b) changes in, lack of enforcement of or funding for emissions programs, regulations or standards; (c) competitive conditions; (d) fluctuations in or the stabilization of the prices of PGM and rare earth metals; (e) intellectual property infringement claims by third parties; (f) supply or delivery interruptions, limitations or failures; and (g) other risks and uncertainties discussed or referenced in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. In addition, any forward-looking statements represent the Company’s estimates only as of the date such statements are and should not be relied upon as representing the Company’s estimates as of any subsequent date. The Company specifically disclaims any obligation to update forward-looking statements. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

CONTACT: Becky Herrick or Cathy Mattison
         LHA (IR Agency)
         +1 415 433 3777
Thursday, October 30th, 2014 Uncategorized Comments Off on (CDTI) Unveils Breakthrough Clean Air Technology

(MOST) Finalist in the 2014 NC Tech Awards, New Media/Digital Technology

The Company’s Groundbreaking Mobile App Development Technology and Customer Successes Have Qualified MobileSmith as a Finalist in North Carolina’s Prestigious Technology Awards Program

RALEIGH, NC–(Oct 29, 2014) – MobileSmith (OTCBB: MOST) has been nominated as a finalist in North Carolina’s statewide technology awards program, in the New Media/Digital Technology category. The finalists were recently announced by the North Carolina Technology Association (NCTA).

MobileSmith’s flagship product, the MobileSmith app development platform, empowers non-programmers to rapidly create, launch and manage custom, native mobile apps for iPhone, iPad, and Android smartphones. MobileSmith’s customers include U.S. Navy, Wake Forest Baptist Medical Center, UNC Rex Health, Robert Wood Johnson University Hospital, Civitas Media, Customized Communications, and many other healthcare, media, and government organizations.

“We are thrilled to be nominated for this prestigious award,” said Robert Hancock, MobileSmith VP of Sales. “As an active member of NCTA, MobileSmith is committed to advancing the innovation in the Research Triangle tech community. Our multiple customers and their award-winning apps can attest to that.”

MobileSmith (OTCBB: MOST) is a complete cloud solution for enterprise mobility and a powerful online platform that allows non-programmers to easily prototype, deploy, and manage native applications for iOS and Android smartphones and iPad tablets without writing a line of code. MobileSmith clients can manage each app from a powerful, dedicated CMS; securely integrate their data sources, and take advantage of proximity beacon technology via MobileSmith/Gimbal integration.

Janna Badalian

Wednesday, October 29th, 2014 Uncategorized Comments Off on (MOST) Finalist in the 2014 NC Tech Awards, New Media/Digital Technology

(FBCD) and COCO-AMO in Discussion With Distributors About Purchasing 3,500 Units

FBC and COCO-AMO Expanding Distribution With Partner Based on Retail Sales

NEW YORK, NY–(Oct 29, 2014) – FBC Holding, Inc. (PINKSHEETS: FBCD) (“FBC” or the “Company”) an international product development company primarily focused on license/creation management and product sales/distribution through DRTV, announced that the company is in discussions with multiple distributors in the US to purchase COCO-AMO products.

“We are building off of the recent successful launch of the COCO-AMO product line, at retail stores and our internet blogging launch strategy. Having impressive retail sales with just one of our products — LOVE – Leave in Conditioner, our distribution partner is considering placing an order for all three products and have the ability to offer their customers a collection,” said Mr. Frank Russo, Chief Executive Officer of FBC Holding, Inc. “Being able to provide our customer base — Hydrate — promotes Moisturizing and Pure – a Sulfate-Free Shampoos, is very exciting and we are going to support our customers as they experience the benefits of using our products.”

Darin Braun, Founder and President of COCO-AMO, said, “COCO-AMO is starting from a small base in the market place but we are already getting interest from ‘Major Retailers’, which means that buyers are starting to hear the buzz about our brand. We are looking to expand our product offerings, most likely in 2015, allowing the retailer to dedicate even more selling space to their consumers that will be raving about the results they are getting from our products. We are just about to receive 7,000 units from our PO and now we might have an order for 3,500 units — that is just crazy but I LOVE it.”

“We continue to build out our web presence through our site, and we continue to receive orders daily. Understanding that we are in a competitive multi-billion dollar Health & Beauty industry, we’ll continue to mix it up, expand our grassroots following and provide products the consumer can see benefits from during use,” said Mr. Russo.

About FBC Interactive Division

FBC Holding’s Interactive Division markets innovative products generally incorporating new proprietary technologies. FBC Interactive, leverages Direct Response Television (DRTV) formats to advertise, market and distribute its products; gaining retail footholds in various markets. FBC Interactive’s market place is diverse, with a primary focus and expertise in toy and entertainment, consumer and health care, products and brands.

About FBC Holding, Inc.

FBC Holdings develops and markets innovative products using a ‘new proprietary’ technology whereby buttons, switches, wires and other electrical components can be printed on nearly any media. Management is experienced in Direct to Consumer Marketing (design, manufacture and market creative products leveraging cutting edge technology). FBC’s market is diverse, covering consumer products, health care related products, and, toy and entertainment products.

Safe Harbor

This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled “Risk Factors” in the Company’s periodic filings with the United States Securities and Exchange Commission, which can be viewed at For all details regarding working interests in all of FBC Holding’s interest, and/or any previous news releases, go to OTC Markets website. You should independently investigate and fully understand all risks before making investment decisions.

Related Links:

For investor relations,
FBC Holding, Inc.
Email Contact

Wednesday, October 29th, 2014 Uncategorized Comments Off on (FBCD) and COCO-AMO in Discussion With Distributors About Purchasing 3,500 Units

(MHCC) Reports Record Third Quarter Revenue

Full Financial Results to Be Announced in Mid-November

GARDEN CITY, NY–(October 29, 2014) – Millennium Healthcare Inc. (OTCQB: MHCC) today announced that revenues for the three months ended September 30, 2014 are expected to be in excess of $6.0 million. This represents significant growth compared with revenue of $490,000 for the comparable 2013 period, and was largely the result of the initial roll out of the Company’s medical device distribution model. During the quarter Millennium Healthcare began the commercial introduction of its first two distributed medical device products, namely VasoScan™, a cardiovascular diagnostic assessment test, and OralCDx™, a non-invasive brush biopsy kit for oral cancer. Millennium intends to continue its model and mission of evaluating early detection and diagnostic devices and continually looks to add and provide additional products to its medical device lines available for distribution.

Commenting on the quarter, David Perry, chief operating officer, said, “Following successful beta testing in June, we began the initial roll out of the VasoScan and OralCDx products to a small portion of our current network of approximately 1,300 primary care physician offices located along the U.S. East Coast. Physician acceptance, measured by utilization as well as reorder rates, was well above our initial expectations so early in the launch process; and we are extremely pleased with the recognition by our early customers of the role these products can play in preventive care and in medical practice economics. We look forward to continuing a managed introduction of these products via our direct sales force and, in time, via sub-distributor partners with the ultimate goal of nationwide coverage.”

Dominick Sartorio, chief executive officer added, “We are excited to continue the commercialization of our device business and to report to our investors on the progress we have made. We believe our third quarter revenue represents the beginning of a significant growth trend for our business, and given our current commitments, we anticipate being able to report significant quarterly revenue for the fourth quarter as well. We believe the industry trend toward early detection diagnostics, combined with our distribution model, highly experienced leadership team, and our exclusive agreements with suppliers are the driving contributors to our current and future success.”

Millennium Healthcare expects to report full financial results for the third quarter, and to hold its first quarterly investor conference call in mid-November.

About Millennium Healthcare Inc.
Millennium Healthcare Inc., through its wholly owned operating subsidiaries, provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting-edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services, and practice development and management services.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains certain statements that may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

Millennium Healthcare Inc.
Joe Giamichael

Kim Sutton Golodetz

Wednesday, October 29th, 2014 Uncategorized Comments Off on (MHCC) Reports Record Third Quarter Revenue

(AMEH) Launches Apollo Palliative Services

GLENDALE, Calif., Oct. 29, 2014  — Apollo Medical Holdings, Inc. (ApolloMed) (OTC-QB: AMEH), an integrated physician-centric healthcare delivery company, today announced the launch of a new subsidiary, Apollo Palliative Services (APS), with the acquisition of majority stakes in both a hospice agency and a home health company.  In conjunction, the Company appointed Liviu Chindris, M.D., as President of APS.

APS will serve as a single source for hospice, palliative care and home health services for ApolloMed’s health plan, hospital and IPA clients in addition to its own subsidiaries and affiliated medical groups: ApolloMed ACO, Maverick Medical Group, AKM Medical Group, ApolloMed Care Clinics and ApolloMed Hospitalists.  The hospice agency serves three counties in Southern California, with an average daily census of 40-60 patients, while the home health agency services three counties in California with an average daily census of 100-140.

The hospice division of APS will serve terminally ill patients and their families through the use of an interdisciplinary team.  Depending on their needs, each hospice patient and their family is assigned a team comprised of a physician, nurse, home health aide, medical social worker, chaplain, dietary counselor and bereavement coordinator.  Hospice and palliative care services are provided in the patient’s home, assisted living/nursing home, or in a hospital.  The home health division will provide direct home skilled nursing and therapy services, as well as specialty programs such as disease management education, nutrition and help with daily living activities.

ApolloMed believes that several factors will contribute to the growth of its hospice and home health business: aging demographics, recognition that in-home services are significantly more cost-effective than institutional care, medical and technological advances that allow more healthcare procedures and monitoring to be provided at home and the benefits of recuperating from an illness or receiving care for a chronic condition in one’s own home.

“I am very excited to join the management team of ApolloMed as we launch Apollo Palliative Services,” stated Dr. Chindris.  “We understand the benefits of hospice, palliative care and home health services for patients and their families and our goal is to make APS one of the leading providers in Southern California.”

“The addition of hospice and home health services will enhance our integrated care model and provide a good platform for the expansion of APS.  We believe that as an efficient operator of integrated healthcare delivery, we are favorably positioned to benefit from current industry trends,” stated Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings.

“We are also very pleased to have Dr. Chindris, one of the earliest physicians to join HealthCare Partners, as a member of the ApolloMed team.  His wealth of knowledge and experience will be a tremendous asset as we continue to grow ApolloMed’s business and expand the services that we provide.”

Dr. Chindris earned his M.D. from the University of Medicine and Pharmacy in Cluj, Romania and completed an internship and residency in internal medicine at Brooklyn Hospital in Brooklyn, New York and Mercy Hospital in Buffalo, New York.  He has held memberships in the American College of Physicians and the American Academy of Hospice and Palliative Medicine.  He is fluent in Romanian, French, Italian, Spanish and English.  Dr. Chindris was a Senior Partner at HealthCare Partners before it was acquired by DaVita in 2012.

About Apollo Medical Holdings, Inc.
ApolloMed is a leading integrated physician-centric healthcare delivery company commited to providing exceptional multi-disciplinary care in the communities it serves.  ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups:  ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA),  ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit

Forward Looking Statements
This press release may contain forward-looking statements, including information about management’s view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. (“the Company”).  In particular, when used in the preceding discussion, where we refer to quarter over quarter revenue growth targeted for the remainder of 2014 and the words “predicts,” “believes,” “expects,” “intends,” “seeks,” “estimates,” “plans,” “anticipates,” and similar conditional expressions or future or conditional verbs such as “will,” “may,” “might,” “should,” “would” and “could” are intended to identify forward-looking statements.  In addition, our representatives may from time to time make oral forward-looking statements.  Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management.  Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected.  Unknown or unpredictable factors also could have material adverse effects on the Company’s future results.  The forward-looking statements included herein are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements.  Accordingly, you should not place undue reliance on these forward-looking statements.  Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended January 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.

The Ruth Group
David Burke
646-536-7009 or via email at

Wednesday, October 29th, 2014 Uncategorized Comments Off on (AMEH) Launches Apollo Palliative Services

(GRAS) Enters Into a Preliminary Agreement With SoFran

WEST PALM BEACH, FL–(Oct 29, 2014) – Greenfield Farms Food, Inc. (“Greenfield” or the “Company”) (OTC: GRAS) and its wholly-owned subsidiary Carmela’s Pizzeria (“Carmela’s”) announced today that they have entered into a preliminary agreement with SoFran, LLC. (“SoFran”) to develop the formation and roll-out of a nationwide franchising program. Terms of the agreement include retaining SoFran to develop a detailed master franchise agreement including all legal and compliance documentation and to evaluate each of the three existing locations in Ohio to determine the best model for the purposes of franchising on a nationwide scale.

The management of Carmela’s has built a proven and replicable model that can be successfully launched in multiple regions of the United States. The agreement with SoFran gives Carmela’s the opportunity to develop and execute a strategy that allows for a timely launch of an appropriate dining concept that’s well suited for future franchisees.

SoFran has an extensive track record in building brands and networks of franchises across the United States. Wayne Mills, President of SoFran commented: “Carmela’s Pizzeria has built a great concept that has the potential to be a recognizable brand throughout the Country. We look forward to working with Carmela’s to launch a successful franchise program.”

SoFran’s management team has over 100 years combined franchising and investment banking experience. SoFran has worked with companies of all sizes and has successfully guided them through the process of structuring new franchises, raising capital and navigating through the legal and compliance documentation required by all franchise owners and future franchisees.

“Partnering with SoFran allows us to leverage their industry experience and successful track record in building Carmela’s into a recognizable brand in the marketplace. Our success will be based on developing a business model for our future franchisors that offers long-term success and sustainability,” commented Mr. Ronald Heineman, President of Greenfield Farms Food, Inc.

Shareholders of the Company can expect to receive additional updates as to the status of these and other developments in the coming weeks.

About Greenfield Farms Food, Inc.
Greenfield is a publicly-traded, nominally capitalized company, operating through its wholly-owned subsidiary Carmela’s Pizzeria CO, Inc. Carmela’s Pizzeria restaurants include pizza buffets, alcohol service, delivery and carry-out, depending on the location. Greenfield has previously been a limited producer and marketer of “grassfed” beef that supplied a North Carolina based grocer.

About Carmela’s Pizzeria
Carmela’s Pizzeria presently has three Dayton, Ohio area locations offering authentic New York style pizza. Carmela’s offers a full service menu for Dine In, Carry out and Delivery as well as pizza buffets in select stores. Carmela’s has been noted in the Dayton Daily News as one of “The Best Pizzerias” in Dayton. Visit the Carmela’s website at:

Safe Harbor for Forward-looking Statements

This news release may contain forward-looking statements that are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, they are based on management’s current beliefs and assumptions as to future events. However, since the company’s operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated or implied. For a more complete discussion of such risks and uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.

Contact Information:
Greenfield Farms Food, Inc.
Henry Fong
(561) 514-9042

Wednesday, October 29th, 2014 Uncategorized Comments Off on (GRAS) Enters Into a Preliminary Agreement With SoFran

(SKVI) Appoints Network Marketing Expert Dean Aldridge as Master Distributor

Kintari Launching Patented Skin Care Product Line

LAS VEGAS, NV–(Oct 29, 2014) – Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) — through its wholly owned subsidiary Kintari International Inc., makers of patented “Youth Renewed” skin care products — is pleased to announce the selection of R. Dean Aldridge in the key role of Master Distributor. Dean will spearhead distributor expansion and development globally.

“We are very pleased to have Dean Aldridge, a world class marketer and sales leader, as our Master Distributor for Kintari,” said Terry Howlett, President of Kintari. “The Master Distributor plays a crucial role in the upward trajectory of the number of distributors that join Kintari and the sales they produce. Dean has exactly the skills and experience to make Kintari a huge success.” He added, “Dean has proven his skills over the past fifteen years in the network marketing industry. He is a multiple award winner and has climbed to the highest level of every company he has been associated with. Dean is often referred to as one of the top recruiters as well as one of the best relationship builders our industry has seen. His expertise has taken him to the top echelons of financial rewards and is touted as one of network marketing’s most distinguished international leaders.”

“When I was introduced to Kintari’s patented technology and then met the corporate leadership team, I knew that this was a special opportunity that I had to get involved with,” said Dean Aldridge. “I was so impressed by the previous network marketing experience of Terry Howlett and Rob Barnes, Kintari’s Director of Sales whose previous network marketing company topped over $20 million per year in sales. This team not only has the industry experience but the understanding of what it takes to succeed, both for Kintari and its distributors. It’s a win-win. I was also impressed by the product line made with the patented Invisicare technology, which has the capability to change the network marketing industry forever. I knew that I had discovered the perfect opportunity; the right products, the right ownership and the right compensation plan — I was in.”

The Kintari product portfolio consists of “Youth Renewed” (YR) anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients are powered by our patented Invisicare® technology, providing consumers with unique, effective skincare benefits which cannot be duplicated.

Kintari has an exclusive license to patented Invisicare products from its parent company Skinvisible Pharmaceuticals, Inc., a science-based research and development company. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription and over-the-counter dermatology products.

About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible’s wholly-owned subsidiary Kintari will commercialize cosmeceutical and OTC products globally through a direct sales channel.

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2014). 

John Pentony
Investor Relations
Ph: 972-292-8930

Wednesday, October 29th, 2014 Uncategorized Comments Off on (SKVI) Appoints Network Marketing Expert Dean Aldridge as Master Distributor

(AMPG) Hiring of JP Fortune Group to Expand Operations, Shareholder Awareness

BOHEMIA, N.Y., Oct. 28, 2014 — AmpliTech Group, Inc. (OTCQB:AMPG) (“AmpliTech” or the “Company”), a trusted provider of RF/microwave, and low noise amplifiers for critical and high-reliability, wireless and commercial applications, is pleased to announce it has engaged JP Fortune Group. JPF is one of North America’s premier small-cap advisory firms. JP Fortune Group will assist the Company in capital structuring, debt management, M&A opportunities, development of a strategic advisory board, market positioning and shareholder communications. JPF will implement a comprehensive financial growth strategy and execute an extensive investor relations campaign. The company’s goal is to increase and exploit opportunity in the marketplace while maintaining a fair market value for its shareholders equity based on its unique technology and expertise.

“We are thrilled to partner with JPF to strengthen our financial operations while informing the investment community about our exciting company and its potential. It is just another step in the right direction with many more to follow,” said Fawad Maqbool, President & CEO of AmpliTech. “We are highly confident our combined efforts will garner successful results in a timely manner,” stated Larry Fortune of JP Fortune Group.

“We believe AmpliTech has developed a premier technology, and we are anxious to communicate the AMPG story to the investment community,” said James Moldenhauer, CEO of JPF.

Interested investors may contact James Moldenhauer at JPF at 714-420-2004.

About AmpliTech Group, Inc.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz – eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers’ own designs. Website:

About JP Fortune Group

JP Fortune Group; a Bryce Holdings, LLC brand is a premier independent investor relations and financial advisory firm, with the depth of experience and expertise to advise companies across a broad spectrum of industries, ranging in revenues from $5 million to over $500 million. With a combined management team experience exceeding 50 years, JP Fortune Group is a leader in providing the highest quality investor relations and financial consulting services for middle market companies across a wide spectrum of industries.

CONTACT: Fawad Maqbool
         AmpliTech Group, Inc.

         Larry Fortune
         Managing Partner
         JP Fortune Group
Tuesday, October 28th, 2014 Uncategorized Comments Off on (AMPG) Hiring of JP Fortune Group to Expand Operations, Shareholder Awareness

(CPPXF) Posts 2014 Annual Results

VANCOUVER, British Columbia, Oct. 28, 2014  — Continental Energy Corporation (OTCQB: CPPXF) (the “Company“) an emerging international energy investment company with operations in Southeast Asia and Tanzania, Africa, today announced the filing on SEDAR of its audited consolidated financial statements for the year ended 30 June 2014. Complete copies of these financial statements are available for download from the SEDAR website at

The Company incurred a net loss of $939,489 during the 2014 fiscal year compared to a net loss of $700,115 during the prior year, an increase of $239,374. The increase in loss was primarily due to the operations of the Company’s Norwegian subsidiary, Visionaire Energy AS (“VEN“) and its two affiliated companies. The Company uses the equity method to account for its portion of the operations of these affiliates and recorded a loss of $311,972 during the 2014 fiscal year while in the prior year; the Company recorded an income of $37,143. The Company had a loss per share of $0.01 in both 2014 and 2013 fiscal years.

As announced on 16 September 2014, the Company agreed to sell its 51% interest in VEN for total consideration of US$1,200,000 to Visionaire Invest AS that owns the other 49% of VEN. The effective date of the sale is set in the agreement at 30 June 2014. The operations of VEN and its affiliates are therefore classified as discontinued operations held for sale. The Company’s investment in its Norwegian subsidiary was reflected at $862,375 on 30 June 2013 and the carrying value of the investment decreased to $559,068 by 30 June 2014.  The sale of VEN is subject to the approval from the shareholders of the Company at the Company’s annual general meeting scheduled for 5 December 2014.

As at 30 June 2014, the Company’s consolidated financial statements reflect a working capital deficit of $693,794. This represents a decrease in the working capital deficit of $50,898 compared to the 30 June 2013 working capital deficit of $744,692. Cash used in operating activities during the 2014 fiscal year totaled $533,013 compared to $189,464 in the prior year. The Company was able to generate more funds in the 2014 fiscal year and make the relevant payments towards its administrative costs. Cash from investing activities during the 2014 fiscal year was $1,219 whereas there was $15,544 expended on such activities during the prior year. Financing activities provided $42,948 in the 2013 fiscal year compared to $761,517 during the 2014 fiscal year primarily from a $750,000 loan that was converted to equity subsequent to 30 June 2014.

The Company also filed on SEDAR its annual reserves report for 2014 in the form referred to in Canadian National Instrument 51-101 “Standards of Disclosure for Oil and Gas Activities”. Complete copies of the reserves report are available for download from the SEDAR website,

On behalf of the Company,

Robert V. Rudman, C.A.
Chief Financial Officer

Further Info:

No securities regulatory authority has either approved or disapproved the contents of this news release.

Forward Looking StatementsAny statements in this news release that are not historical or factual at the date of this release are forward looking statements. There are many factors which may cause actual performance and results to be substantially different from any plans or objectives described in any forward looking statements. Readers should also refer to the risk disclosures outlined in the Company’s regulatory disclosure documents filed with the Securities and Exchange Commission available at The Company assumes no obligation to update the information in this release.

Tuesday, October 28th, 2014 Uncategorized Comments Off on (CPPXF) Posts 2014 Annual Results